25T-NBOMe Stats & Data

25T-NBOMe (NBOMe-2C‑T) is a potent, little-studied analogue of 2C‑T derivatives where an N‑(2‑methoxybenzyl) group confers sub‑milligram activity. Oral bioavailability is unreliable across NBOMes; swallowing does not guarantee inactivity—avoid relying on this to “test” blotters. Misrepresented blotter is common; multi‑reagent testing (e.g., Ehrlich to detect indoles for LSD, plus Hofmann/Marquis/Mecke) helps, but very small NBOMe loads can yield weak/no color, and doped tabs may fool Ehrlich—lab drug checking is safest. Insufflation markedly increases risk of severe toxicity (hyperthermia, seizures, rhabdomyolysis) reported for the NBOMe class; avoid nasal, rectal, IM, and IV routes. Because active doses are so small, volumetric dosing in ethanol/water using accurately labeled amber glass is strongly recommended; evaporation of solvent can silently concentrate solutions. Expect rapid tolerance after one experience; redosing the same day adds cardiovascular strain with limited benefit. Individuals with cardiovascular disease, hypertension, Raynaud’s, seizure history, or significant psychiatric instability should avoid NBOMe compounds. Storage stability improves when protected from heat, light, moisture, and oxygen; store blotter/solution cool and dark. Nomenclature note: “25T‑NBOMe” is ambiguous and may refer to several 2C‑T homologues (e.g., 25T2/25T4); potency can vary—treat all as highly potent and experimental.